Nicholas Investment Partners LP Invests $2.07 Million in Fulcrum Therapeutics, Inc. $FULC

Nicholas Investment Partners LP purchased a new position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 182,961 shares of the company’s stock, valued at approximately $2,069,000. Nicholas Investment Partners LP owned 0.34% of Fulcrum Therapeutics at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Aberdeen Group plc grew its holdings in Fulcrum Therapeutics by 135.0% during the third quarter. Aberdeen Group plc now owns 137,961 shares of the company’s stock valued at $1,269,000 after purchasing an additional 79,265 shares during the period. Braidwell LP acquired a new position in Fulcrum Therapeutics during the third quarter valued at approximately $2,019,000. Boothbay Fund Management LLC grew its holdings in Fulcrum Therapeutics by 104.2% during the third quarter. Boothbay Fund Management LLC now owns 678,414 shares of the company’s stock valued at $6,241,000 after purchasing an additional 346,136 shares during the period. Suvretta Capital Management LLC grew its holdings in Fulcrum Therapeutics by 5.9% during the third quarter. Suvretta Capital Management LLC now owns 5,381,000 shares of the company’s stock valued at $49,505,000 after purchasing an additional 298,100 shares during the period. Finally, GSA Capital Partners LLP grew its holdings in Fulcrum Therapeutics by 256.4% during the third quarter. GSA Capital Partners LLP now owns 116,068 shares of the company’s stock valued at $1,068,000 after purchasing an additional 83,505 shares during the period. Institutional investors and hedge funds own 89.83% of the company’s stock.

Fulcrum Therapeutics Stock Down 2.8%

Shares of FULC stock opened at $3.45 on Friday. The company’s fifty day simple moving average is $6.59 and its 200-day simple moving average is $8.82. The firm has a market cap of $229.87 million, a PE ratio of -3.00 and a beta of 2.93. Fulcrum Therapeutics, Inc. has a 12 month low of $2.83 and a 12 month high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings data on Monday, April 27th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.06. On average, equities analysts predict that Fulcrum Therapeutics, Inc. will post -0.76 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on FULC. Piper Sandler cut shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating and set a $3.00 price objective for the company. in a report on Tuesday, June 2nd. Jefferies Financial Group set a $4.00 price objective on shares of Fulcrum Therapeutics in a report on Tuesday, June 2nd. Wall Street Zen upgraded shares of Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 2nd. Stifel Nicolaus cut shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 price objective for the company. in a report on Tuesday, June 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Tuesday, April 21st. One analyst has rated the stock with a Buy rating, seven have given a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Reduce” and a consensus target price of $8.20.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.